RxDoctor Payments Data

Robert Mitchell, MD

Gastroenterology · Corpus Christi, TXNPI 1184694697

Payments from drug & device makers

$1,689in general payments, 2019–2025

Across 68 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Braintree Laboratories, Inc.$205
  • Gilead$138
  • Takeda Pharmaceuticals U.S.A., Inc.$76
  • Johnson & Johnson$72
  • Ardelyx, Inc.$48
  • plus $139 from 7 others

What the payments were for

  • Food & beverage$1,49689%
  • Education$91%
  • Gifts$18411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,689 in reported general payments places this provider in the 30th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$126,924
Medicare patients
588
Services billed
1,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin48$143,602
LinzessLinaclotide79$62,265
ClenpiqSod Picosulf/Mag Ox/Citric Ac202$35,391
ZenpepLipase/Protease/Amylase15$26,581
Mesalamine62$20,402
Mesalamine ErMesalamine31$8,799
Dexlansoprazole DrDexlansoprazole30$8,637
Budesonide DrBudesonide24$6,847
PertzyeLipase/Protease/Amylase13$6,801
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates99$6,170
Rabeprazole Sodium194$5,181
Ursodiol26$4,748
CholestyramineCholestyramine (With Sugar)31$2,999
Omeprazole239$2,942
Cyclosporine ModifiedCyclosporine, Modified12$2,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$14$143,60248 claims
AbbVieLinzess$1,011$62,26579 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →